Cell cycle-based antibody selection for suppressing cancer cell growth

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Cell cycle arrest and programmed cell death are critical in cancer development.
• Targeting cell fate decisions offers a therapeutic strategy for cancer.
• Inducing cell cycle regulatory proteins in tumor cells is a key goal in cancer therapy.

Purpose of the Study:

• To present a novel antibody selection method for inhibiting cancer growth.
• To identify antibodies that induce cancer cells into G0/G1 phase, promoting cell cycle arrest and apoptosis.
• To investigate the therapeutic potential of targeting serine protease 3 (PRSS3) in solid cancers.

Main Methods:

• Antibody library screening using fluorescence-activated cell sorting (FACS) assays.
• Cell cycle analysis to identify antibodies inducing G0/G1 phase arrest.
• Mechanistic studies to elucidate the interaction between T1 antibody and PRSS3.

Main Results:

• The T1 antibody was identified as effective in suppressing cancer cell proliferation.
• PRSS3 was confirmed as the target antigen for the T1 antibody.
• PRSS3 was shown to regulate tumor cell proliferation and apoptosis via interaction with the T1 antibody.

Conclusions:

• PRSS3 is a promising therapeutic target for solid cancer treatment.
• The developed antibody screening approach is effective and broadly applicable to various diseases.
• Targeting PRSS3 with antibodies can induce cell cycle arrest and apoptosis, inhibiting cancer growth.